Does DUVELISIB Cause Malignant neoplasm progression? 38 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 38 reports of Malignant neoplasm progression have been filed in association with DUVELISIB (COPIKTRA). This represents 5.0% of all adverse event reports for DUVELISIB.
38
Reports of Malignant neoplasm progression with DUVELISIB
5.0%
of all DUVELISIB reports
15
Deaths
20
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DUVELISIB?
Of the 38 reports, 15 (39.5%) resulted in death, 20 (52.6%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DUVELISIB. However, 38 reports have been filed with the FAERS database.
What Other Side Effects Does DUVELISIB Cause?
Product use in unapproved indication (162)
Diarrhoea (110)
Death (89)
Fatigue (75)
Prescribed underdose (63)
Off label use (57)
Nausea (49)
Pneumonia (40)
Pyrexia (40)
Rash (33)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DUVELISIB Alternatives Have Lower Malignant neoplasm progression Risk?
DUVELISIB vs DYDROGESTERONE
DUVELISIB vs EBASTINE
DUVELISIB vs ECALLANTIDE
DUVELISIB vs ECONAZOLE
DUVELISIB vs ECULIZUMAB